Clinical Trials Browser

Phase 1/2 × tosedostat × Plasma cell × Clear all

NCT00689000 2010-10-22

Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Phase 1/2 Completed

MyeloidOther hematologic neoplasmPlasma cell

Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms